Citius Pharmaceuticals, Inc. (CTXR)
Company Description
Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy.
It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.
The company was founded in 2007 and is headquartered in Cranford, New Jersey.
Country | United States |
Founded | 2007 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 22 |
CEO | Leonard L. Mazur |
Contact Details
Address: 11 Commerce Drive, 1st Floor Cranford, New Jersey 07016 United States | |
Phone | (908) 967-6676 |
Website | citiuspharma.com |
Stock Details
Ticker Symbol | CTXR |
Exchange | NASDAQ |
Fiscal Year | October - September |
Reporting Currency | USD |
CIK Code | 0001506251 |
CUSIP Number | 17322U207 |
ISIN Number | US17322U2078 |
Employer ID | 27-3425913 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Leonard L. Mazur | Co-Founder, Chief Executive Officer, Chairman and Secretary |
Myron Z. Holubiak | Co-Founder and Executive Vice Chairman |
Dr. Myron S. Czuczman M.D. | Executive Vice President and Chief Medical Officer |
Jaime Bartushak | Chief Business Officer, Chief Financial Officer and Chief Accounting Officer |
Gary F. Talarico | Executive Vice President of Operations |
Ilanit Allen | Vice President of Investor Relations and Corporate Communications |
Dr. Alan Lader Ph.D. | Senior Vice President and Head of Clinical Operations and Quality Assurance |
Dhananjay G. Wadekar | Senior Vice President of Business Strategy |
Kelly Creighton Ph.D. | Executive Vice President of Chemistry, Manufacturing and Controls |
Nikolas Burlew | Executive Vice President of Quality Assurance |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 18, 2024 | 8-K | Current Report |
Mar 13, 2024 | 8-K | Current Report |
Mar 1, 2024 | EFFECT | Notice of Effectiveness |
Feb 23, 2024 | S-3 | Registration statement under Securities Act of 1933 |
Feb 23, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Feb 15, 2024 | 8-K | Current Report |
Feb 14, 2024 | 10-Q | Quarterly Report |
Feb 14, 2024 | 8-K | Current Report |
Jan 31, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Jan 26, 2024 | ARS | Filing |